CliffBio
biologic

Kalbitor

ecallantide

Loss of exclusivityDecember 2021projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameKalbitor
Active ingredientecallantide
Strength10MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalDecember 2009
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Kalbitor patent cliff — loss of exclusivity December 2021 | CliffBio